Halozyme Therapeutics, Inc. (HALO) Dividend History

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative biologic and drug delivery technologies. They are known for their enzyme-based platforms that enhance the absorption and distribution of therapeutic proteins and peptides, supporting the development of targeted cancer treatments, autoimmune disorders, and other medical conditions. The company's proprietary enzyme, ENHANZE, is used in collaborations with major pharmaceutical companies to improve the efficacy and administration of various biologics.

12390 El Camino Real, San Diego, CA, 92130
Phone: (858) 794-8889
Website: https://www.halozyme.com

Dividend History

Halozyme Therapeutics, Inc. currently does not pay dividends

Company News

argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

argenx announced FDA approval of a new self-injection option for VYVGART Hytrulo, providing patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy more flexibility and independence in their treatment.

GlobeNewswire Inc.
Needle Free Injectors Market Is Expected To Reach a Revenue Of USD 2,980.9 Million By 2033, At 8.1% CAGR: Dimension Market Research

The global needle-free injectors market is projected to grow from USD 1,478.9 Million in 2024 to USD 2,980.9 Million by 2033, at a CAGR of 8.1%. These injectors deliver medications and vaccines without traditional needles, reducing pain and needle-related risks. The adoption of advanced drug delivery technologies is driving market growth.

GlobeNewswire Inc.

Featured Companies: PFE
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research

Dividend data last updated 06/07/2025 15:38:28 UTC